Praxis Begins Patient Recruitment for Pediatric Epilepsy Research Program
Brentwood, TN
Praxis a company specializing in centralized patient recruitment and retention for clinical research studies, will provide patient recruitment services to a top pharmaceutical company for a study on pediatric epilepsy. This study explores a drug’s effectiveness in very young children. Praxis’ experiences with hard to reach and specialized patient populations is extensive and includes a number of pediatric trials.
Praxis’ successful experiences with hard to reach and specialized patient populations is extensive, and includes a number of pediatric trials. Praxis has helped sponsors successfully enroll pediatric studies:
on average 2 months ahead of schedule
with retention rates most often at 96%, and
with sponsors achieving ROI from ~$1M to ~$3M
“Any time we create and manage a trial involving children there is a real added focus on understanding the mother’s perspective and concerns. We seek to really connect with the mother through images and words that speak to the heart. And by providing content that educates and informs the mom about options, the indication, and the medical research study at hand.” Donna Beasley, VP of operations.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
